Psychedelic-Assisted Therapy: A Clinical Reference

Overview

As of early 2026, no psychedelic-assisted therapy is FDA-approved in the United States. The field is in a complicated position: the Phase 3 data that initially looked pivotal has run into regulatory headwinds, and the clearest near-term approval candidate (psilocybin) is still in active trials. Meanwhile, state-regulated programs (Oregon 2023, Colorado 2024) have opened a parallel non-medical access pathway that many patients will ask about.

This page is written for clinicians who need to answer those patient questions with accuracy and without either excessive hype or reflexive dismissal.

Regulatory status (2026)

MDMA-assisted therapy

Chemical structure of MDMA. Structurally related to amphetamine with the methylenedioxy ring substitution that gives it distinct pharmacology compared to classical stimulants.

Therapeutic rationale for PTSD

Under MDMA, patients appear to be able to re-engage with traumatic memories without the typical hyperarousal response — which is sometimes described as an expanded "window of tolerance" between hypo- and hyper-arousal states. This allows trauma-focused psychotherapy to proceed with material that would otherwise be destabilizing, potentially enabling memory reconsolidation and fear extinction.

Supporting evidence:

• Young et al. 2015 — MDMA enhances fear extinction learning in animal models
• Sripada et al. 2012 — baseline connectivity abnormalities in PTSD (amygdala-insula hyperconnectivity, reduced amygdala-hippocampal positive connectivity, reduced amygdala-ACC anticorrelation) provide a mechanistic target
• Singleton et al. 2023 — MDMA-assisted therapy appears to modify amygdala-insular functional connectivity, with changes correlating with symptom improvement

The amygdala is central to threat processing and a primary target of PTSD pathophysiology. PTSD involves amygdala hyperactivity and altered connectivity with prefrontal regulatory regions; MDMA appears to modify these patterns during therapy sessions.

MDMA pharmacology

Pharmacodynamics

• Inhibits serotonin reuptake (SERT) and triggers serotonin release via VMAT-2 interaction
• Also inhibits dopamine transporter (DAT) and norepinephrine transporter (NET), increasing synaptic cleft concentrations of both
• MAO inhibition contributes to elevated monoamine levels
• Downstream: oxytocin and arginine vasopressin release — likely contributors to the prosocial/empathogenic subjective effect

Acute physical effects

Toxicity considerations

"Dosis sola facit venenum" — Paracelsus. The dose makes the poison. Most recreational fatalities involve blood levels 10–40x the typical therapeutic range, often with co-intoxicants or unintended dose escalation.

At higher blood levels, possible complications include:

• Hepatotoxicity
• Cardiac arrhythmia, MI
• Intracranial aneurysm rupture, stroke
• Hyperthermia with secondary rhabdomyolysis, myoglobinuria, DIC, acute liver injury
• Dehydration or dilutional hyponatremia (paradox: water intoxication from intentional rehydration)
• Seizures
• Serotonin syndrome (especially with serotonergic medications)

Mustafa et al. 2020 review of MDMA neurotoxicity suggests multiple mechanisms (direct neuronal effects and indirect disruption of neurotransmitter regulation). Clinical relevance at therapeutic doses is unclear.

MDMA: evidence & FDA rejection

Phase 3 trials (MAPP1, MAPP2)

At 18 weeks: 67–71% of MDMA group no longer met DSM-5 PTSD criteria (vs. 32–48% placebo); 46% met remission criteria (vs. 21% placebo).

The August 2024 FDA Complete Response Letter

Despite positive Phase 3 primary outcomes, the FDA declined approval. The CRL was publicly released in September 2025 as part of a broader FDA transparency initiative. Key concerns:

• Functional unblinding: the subjective effect of MDMA is distinctive enough that participants generally know which arm they're in, undermining blinded placebo comparison
• Safety documentation gaps: particularly around systematic documentation of abuse-related adverse events
• Questions about durability of the antidepressant/anti-PTSD effect over longer follow-up
• Therapist oversight and protocol consistency concerns following the ethics violation disclosure
• Limited patient diversity in trial populations
• Unclear separation of drug effect from psychotherapy effect

Psilocybin-assisted therapy

Therapeutic rationale for depression

Unlike daily monoamine antidepressants, the psilocybin-assisted therapy model proposes that a small number of high-dose sessions with structured psychotherapy can produce durable clinical improvement. Proposed mechanisms:

• 5-HT_2A receptor agonism → altered cortical network dynamics, including default mode network (DMN) disintegration and increased global connectivity during the acute experience
• Neuroplasticity effects: preclinical data suggests psilocybin increases dendritic spine density, BDNF signaling, and structural plasticity
• "Pivotal mental states": the subjective experience itself — particularly features like mystical-type experience, ego dissolution, psychological insight — correlates with clinical outcome in multiple trials, suggesting the experience may be psychotherapeutically active rather than merely accompanying the biological effect

Clinical pharmacology

Psilocybin evidence

The psilocybin evidence base for depression is smaller than MDMA for PTSD but showing more consistent signals and less trial conduct controversy. Compass Pathways is the leading commercial sponsor; Usona Institute is running a parallel non-profit program.

Context on effect sizes

Limitations of the evidence base

• Functional unblinding concern applies here as well — though Compass Pathways has partially addressed this by using low-dose (1 mg) psilocybin rather than inert placebo as control
• Sample sizes smaller than Phase 3 standards for MDD
• Expectancy effects in highly-motivated trial participants may inflate effect sizes
• Durability data is limited; relapse rates after single dose appear meaningful
• Cardiac safety data at scale is pending

Mechanism comparison: psychedelics vs. ketamine

Classical psychedelics (psilocybin, LSD, DMT, mescaline) and MDMA are often grouped under "psychedelic-assisted therapy," but the mechanisms are quite different — and both are distinct from ketamine.

The practical implication: these aren't interchangeable treatments. Mechanism-based matching of compound to indication is part of the field's current theoretical basis, though evidence-based matching is still evolving.

Clinical considerations

Common patient situations

• Patient asking about psychedelic retreats abroad — worth discussing the quality-control variability, absence of US medical accountability, risks for anyone with cardiovascular or psychiatric history involving psychosis, difficulty integrating experiences without ongoing US-based support
• Patient considering Oregon/Colorado state programs — these are real legal pathways but not medical treatment; facilitators aren't medical professionals; screening is variable; worth knowing if your patient is going this route for coordination and safety planning
• Patient with TRD asking whether to wait for psilocybin approval — ketamine is available now with comparable evidence in TRD; suggesting "wait 1–3 years" isn't usually the right answer for someone actively suffering
• Patient with severe PTSD after 2024 FDA decision — first-line evidence-based trauma therapies (PE, CPT, EMDR) retain their place; TMS for PTSD is FDA-cleared; ketamine has evidence in PTSD as well

Cautions regardless of access path

• Psychosis risk: classical psychedelics are contraindicated in patients with personal or family history of schizophrenia or bipolar I; can precipitate first episodes
• Cardiovascular: 5-HT_2B agonism carries valvulopathy risk with chronic use; acute BP/HR elevation requires cardiovascular screening
• Serotonin syndrome: interactions with MAOIs and potentially with SSRIs/SNRIs (though SSRI interactions with psilocybin may actually reduce psilocybin effects, creating different concerns)
• Psychological preparation: the therapeutic model depends on preparation and integration; access pathways that skip these are higher-risk
• Destabilization: significant proportion of patients report challenging or destabilizing experiences that may require clinical support afterward

Referring & advising patients

Patient asks: "Can you refer me to a psychedelic therapy program?"

The honest answer in early 2026: in the US medical system, no — unless you're enrolling them in a clinical trial. Most academic psychiatric centers have active trials; ClinicalTrials.gov is searchable by condition and location. Major US programs include Johns Hopkins Center for Psychedelic and Consciousness Research, NYU Center for Psychedelic Medicine, UCSF Translational Psychedelic Research Program, Mount Sinai, and various Compass and Usona trial sites.

Patient asks: "Should I do this underground or abroad?"

A reasonable approach is honest, non-judgmental risk discussion rather than reflexive advocacy or opposition:

• Medical screening abroad is often inadequate for cardiovascular contraindications
• Drug quality/dose control varies enormously
• If something goes wrong psychologically, the patient is far from their support system and usual providers
• Retreat facilitators often aren't clinicians and may not recognize when a participant needs medical or psychiatric intervention
• Integration support after returning home is usually absent
• For many patients, available US treatments (ketamine, ECT, TMS, intensive psychotherapy) are underutilized before pursuing these alternative pathways

Alternative framings that often help

• For TRD: "There's a treatment with similar mechanism and speed that's available now — ketamine or esketamine. If we address this with current tools and it doesn't work, psilocybin will likely be available in 1–3 years."
• For PTSD: "MDMA-assisted therapy is probably 3–5 years away in the best case. In the meantime, there are evidence-based trauma therapies that work for most patients, and some emerging neuromodulation options we can consider."
• For meaning/existential issues: it's worth acknowledging that some patient interest in psychedelics isn't really about symptom treatment — it's about meaning-making, end-of-life concerns, or spiritual questions that aren't well-served by any current psychiatric treatment. That's a real clinical conversation even when the answer is "I can't offer that legally right now."

References

Key primary sources. Note that three earlier MDMA-AT papers in Psychopharmacology were retracted in August 2024; retracted papers are not listed here.

MDMA: Phase 3 trials

1. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021;27(6):1025–1033. doi:10.1038/s41591-021-01336-3
2. Mitchell JM, Ot'alora GM, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 2023;29(10):2473–2480.

MDMA: mechanism and pharmacology

1. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 2001;165(7):917–928.
2. Young MB, Andero R, Ressler KJ, Howell LL. 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry 2015;5(9):e634.
3. Sripada RK, King AP, Garfinkel SN, et al. Altered resting-state amygdala functional connectivity in men with posttraumatic stress disorder. J Psychiatry Neurosci 2012;37(4):241–249.
4. Singleton SP, Wang JB, Mithoefer M, et al. Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder. Front Psychiatry 2023;13:947622.
5. Sessa B, Higbed L, Nutt D. A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front Psychiatry 2019;10:138.
6. Mustafa NS, Bakar NHA, Mohamad N, et al. MDMA and the brain: a short review on the role of neurotransmitters in neurotoxicity. Basic Clin Neurosci 2020;11(4):381–388.
7. Verrico CD, Miller GM, Madras BK. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters. Psychopharmacology 2007;189(4):489–503.

MDMA: regulatory

1. US Food and Drug Administration. Complete Response Letter, NDA 215455 (midomafetamine capsules), August 8, 2024. Publicly released September 4, 2025.
2. Lykos Therapeutics press release: Lykos Therapeutics announces Complete Response Letter for midomafetamine capsules for PTSD, August 9, 2024.

Psilocybin: clinical trials

1. Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2021;78(5):481–489.
2. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021;384(15):1402–1411.
3. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 2022;387(18):1637–1648.
4. Raison CL, Sanacora G, Woolley J, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 2023;330(9):843–853.